{"grounding": "In ligand bias different agonist drugs are thought to produce distinct signaling outputs when activating the same receptor. If these signaling outputs mediate therapeutic versus adverse drug effects, then agonists that selectively activate the therapeutic signaling pathway would be extremely beneficial. It has long been thought that \u03bc-opioid receptor agonists that selectively activate G protein\u2013 over \u03b2-arrestin-dependent signaling pathways would produce effective analgesia without the adverse effects such as respiratory depression. However, more recent data indicate that most of the therapeutic and adverse effects of agonist-induced activation of the \u03bc-opioid receptor are actually mediated by the G protein\u2013dependent signaling pathway, and that a number of drugs described as G protein biased in fact may not be biased, but instead may be low-intrinsic-efficacy agonists. In this review we discuss the current state of the field of bias at the \u03bc-opioid receptor and other opioid receptor subtypes.", "generated_text": "Biased agonism at opioid receptors has emerged as a critical mechanism underlying the development of therapeutic and adverse effects associated with opioid medications. Studies have elucidated the complex interplay between opioid receptor G protein-coupled receptor (GPCR) signaling and \u03b2-arrestin-mediated desensitization. Ligand bias, where specific agonists preferentially activate one G protein over another, has been implicated in the modulation of opioid receptor function. This review synthesizes recent findings on the molecular mechanisms underlying biased agonism at opioid receptors, with a focus on the role of \u03b2-arrestin in regulating receptor desensitization and internalization. The implications of biased agonism for the design of novel therapeutic agents and the prevention of opioid-related addiction are also discussed. Overall, this review highlights the need for a more nuanced understanding of opioid receptor function and the development of targeted therapies to mitigate the risks associated with opioid use.", "label": 1}